Sysmex Inostics
Kellie Quash is an experienced professional in the field of clinical laboratory science and quality management, currently serving as Quality Manager at Sysmex Inostics since June 2023. Before this role, Kellie held the position of CLIA Consultant at QIAGEN and served as Director of CLIA Quality at Curative. With a background that includes various leadership roles in quality management and clinical operations at organizations such as the National Institutes of Health and Holy Cross Health, Kellie has a strong foundation in medical technology. Kellie earned a Master's degree in Business Administration and Management from the University of Maryland Global Campus and a Bachelor's degree in Clinical Laboratory Science from Howard University.
Sysmex Inostics
Leaders of the Global Liquid Biopsy Revolution As pioneers in blood-based cell-free tumor DNA (ctDNA) mutation detection, Sysmex Inostics has provided custom assays and CLIA-certified lab services to leading BioPharma companies over the last 10 years with the overall goal: to develop therapeutics that extend lives and provide diagnostics to monitor response to therapy, identify targetable resistance alterations, and detect minimal residual disease (MRD). SafeSEQ NGS technology can detect clinically relevant mutations in circulating tumor DNA (ctDNA) with robust detection as low as 0.03% mutant allele frequency (MAF), thus ensuring reliable molecular information for real-time therapy selection as well as monitoring of tumor response from across a broader range of genomic regions.